Aerobic Training Effect on Blood S-Klotho Levels in Coronary Artery Disease Patients | Abstract
Clinical & Experimental Cardiology

Clinical & Experimental Cardiology
Open Access

ISSN: 2155-9880


Aerobic Training Effect on Blood S-Klotho Levels in Coronary Artery Disease Patients

Moran Saghiv, Chris Sherve, David Ben-Sira, Michael Sagiv and Ehud Goldhammer

Rationale: Aerobic exercise and Klotho gene expression reduce the risk of cardiovascular events in patients with prior coronary artery disease (CAD) thus, aerobic exercise may create a decreased risk of mortality.
Objective: The purpose of the present study was to compare the association between s-klotho serum levels and IGF-1 levels in 3 groups: 60 untrained coronary artery disease patients (CAD) age 52.6 ± 2 years, 60 active participants with CAD in supervised aerobic programs for at least 12 months (4-5 times•wk-1) age 53.0 ± 2 years, and 40 untrained healthy males, age 53.6 ± 1.5 years to assess association of aerobic training and s-klotho activity.
Methods and results: Blood samples were drawn from a forearm vein after overnight fasting, s-Klotho levels in the serum were analyzed using an α-klotho Enzyme Linked Immunosorbent Assay ELISA kit, while, IGF-1 was measured by a chemiluminescent immunometric method. Significant (p>0.05) differences were noted between the aerobically trained CAD patients and both untrained groups: CAD patients and healthy subjects with regard to s- Klotho (491 ± 66, 386 ± 70 and 418 ± 81 pg•mL-1 respectively), IGF-1 (82 ± 12, 106 ± 21 and 98 ± 14 nmol•L-1 respectively) and maximal oxygen uptake (42.1 ± 4.5, 31.9 ± 3.9 and 35.8 ± 2.9 mL•kg-1•min-1 respectively).
Conclusions: S-Klotho and aerobic exercise training are factors that may promote upgrading capacities of the CAD patients. Inflection of Klotho expression through aerobic training represents a relationship that may contribute to the explanation of the effects of aerobic activity on CAD patients. In addition, findings suggest that atenolol treatment does not influence s-Klotho and IGF-1 levels in CAD patients treated with atenolol.